Published: 2021-09-28

Nationwide surveillance for Telmisartan alone or with combination at real world therapy in Indian patients with hypertension (START)

Manoj B. Chopda, Sunil G. Gadkar, Yashwanth A. Lakshmaiah, Ravi K. Lambata, Dhammadeep C. Dabhade, Sanket R. Newale


Background: Angiotensin receptor blockers (ARBs) are amongst the most preferred class of antihypertensive as reported at various evidences or guidelines. However, choice amongst ARBs differs between practicing physicians in real-life scenario. This survey aimed to understand the usage preferences of telmisartan therapy alone and in combination for treating hypertension (HT) among practitioners at various clinical settings in real-life scenario in India.

Methods: A cross‑sectional survey was conducted with a pre-validated survey questionnaire consisting of 15 questions pertaining to the telmisartan and its combination usage in HT management. Total 498 registered medical practitioners (mostly physicians and cardiologists) had participated in survey. They were approached for seeking their perception, opinions, and prescribing behaviour. Categorical data was summarized by number (n) and percentage (%) in each category. Data were summarised in frequency tables.

Results: Key findings from the data analysed were as follows: Around 20-40% of patients been reported to have co-morbid hypertension and diabetes as reported by majority of the physicians. Preferred class of drug in patients with hypertension with diabetes reported to be ARB. Around 90.36% of doctors reported that telmisartan was the most preferred ARB in patients with hypertension associated with high cardiovascular risk. Around 90.76% of doctors reported for their preference for telmisartan in patients with hypertension for 24-hr BP control. Around 82.93% of doctors preferred telmisartan in patients with hypertension and stroke/post-MI status.

Conclusions: Indian healthcare practitioners prefer telmisartan as the most preferred ARB either alone or in a combination in patients with hypertension, including those with comorbidities.


Hypertension, Angiotensin receptor blockers, Telmisartan, Combination therapy

Full Text:



Tiruneh SA, Bukayaw YA, Yigizaw ST, Angaw DA. Prevalence of hypertension and its determinants in Ethiopia: A systematic review and meta-analysis. PLoS One. 2020;15(12):e0244642.

Gupta, R., Gaur, K. S. Ram, C.V. Emerging trends in hypertension epidemiology in India. J Hum Hypertens. 2019;33:575-87.

Musini VM, Gueyffier F, Puil L, Salzwedel DM, Wright JM. Pharmacotherapy for hypertension in adults aged 18 to 59 years. Cochrane Database Syst Rev. 2017;8(8):CD008276.

Ramakrishnan S, Ingole S, Dey A, Jain R. Management of hypertension: Insights into prescribing behavior with focus on angiotensin receptor blockers. J Pract Cardiovasc Sci. 2017;3:22-7.

Khan MY, Pandit S, Abdulkutty J, Navasundi G, Hazra PK, Phadke U et al. Effectiveness of Telmisartan on Blood Pressure Control in Hypertensive Patients in India: A Real-World Retrospective Study from Electronic Medical Records. Cardiol Ther. 2021;10:255-69.

Chen R, Suchard MA, Krumholz HM. Comparative First-Line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: A multinational cohort study. Hypertension. Published online. 2021.

Yusuf S, Teo KK, Pogue J. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-59.

S Yusuf, K Teo, C Anderson. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174-83.

Mallat SG. What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment? Cardiovasc Diabetol. 2012;11:32.